Appia Bio
Antoni Ribas, MD, PhD is professor of medicine at the David Geffen School of Medicine at UCLA; director of the UCLA Jonsson Comprehensive Cancer Center Tumor Immunology Program; and director of the Parker Institute for Cancer Immunotherapy Center at UCLA. He is an internationally recognized physician-scientist whose translational and clinical research in immuno-oncology focuses on developing new therapeutic options for malignant melanoma patients. He is an elected member of the American Society of Clinical Investigation, the recipient of an AACR Richard and Hinda Rosenthal Award and a NCI Outstanding Investigator Award. Dr. Ribas earned his doctorate from the Autonomous University of Barcelona and his medical degree from the University of Barcelona.
This person is not in the org chart
This person is not in any offices
Appia Bio
Appia Bio is an early-stage biotechnology company based in Los Angeles, California. Founded in 2020, Appia Bio is focused on discovering and developing engineered allogeneic cell therapies across a broad array of indications with a scalable technology platform that increases access for patients. With its ACUA (Appia Cells Utilized for Allogeneic) technology platform, Appia Bio leverages the biology of lymphocyte development with chimeric antigen receptor (CAR) and T-cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-iNKT) cell subtypes from hematopoietic stem cells (HSCs).